HTL Biotechnology Acquires Modern Meadow's Beauty & Biomedical Division

May 6, 2024

HTL Biotechnology has acquired the beauty and biomedical division of American company Modern Meadow, including its recombinant proteins platform and leading human recombinant collagen type III (rhCOL3) technology. The deal expands HTL's biopolymer portfolio and R&D/manufacturing capabilities, strengthens its presence in North America, and accelerates development of cosmetic and medical-grade recombinant collagen products.

Buyers
HTL Biotechnology
Targets
Modern Meadow (beauty & biomedical division)
Sellers
Modern Meadow
Industry
Biotechnology
Location
New Jersey, United States
Transaction Type
Divestiture

Explore More

Related Acquisitions

Track M&A activity that matters to you

Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.